Altered hepatic metabolic activity in patients with hepatic steatosis on FDG PET/CT

American Journal of Roentgenology

Volumn 196, Issue 1, 2011, Pages 176-180

  Abikhzer, Gad ^a   Alabed, Yazan Z ^a   Azoulay, Laurent ^a,b   Assayag, Jonathan ^c   Rush, Chris ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

FDG; Hepatic steatosis; PET CT; Standardized uptake value

Indexed keywords

ADULT; ARTICLE; BODY WEIGHT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FATTY LIVER; FEMALE; HUMAN; LEAN BODY WEIGHT; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY;

CASE-CONTROL STUDIES; FATTY LIVER; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 78650832932     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4679     Document Type: Article

References (26)

1. Mergo PJ, Ros PR, Buetow PC, Buck JL. Diffuse disease of the liver: radiologic-pathologic correlation. RadioGraphics 1994; 14:1291-1307
2. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol 2007; 22:778-787
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346:1221-1231
4. Som P, Atkins HL, Bandoypadhyay D, et al. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med 1980; 21:670-675 (Pubitemid 10034639)
5. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S, Alavi A. 18F-FDG PET in characterizing adrenal lesions detected on CT or MRI. J Nucl Med 2001; 42:1795-1799 (Pubitemid 34016347)
6. 18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med 2004; 45:2058-2062
7. Tournoy KG, Madddens S, Gosselin R, Van Maele G, van Meerbeeck JP, Kelles A. Integrated FDG-PET/ CT does not make invasive staging of the intrathoracic lymph nodes in non-small cell lung cancer redundant: a prospective study. Thorax 2007; 62:696-701
8. Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood 1998; 91:3340-3346 (Pubitemid 28193885)
9. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998; 133:510-515
10. Delbeke D, Rose DM, Chapman WC, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999; 40:1784-1791
11. Yoshida Y, Kurokawa T, Sawamura Y, et al. Comparison of 18F-FDG PET and MRI in assessment of uterine smooth muscle tumors. J Nucl Med 2008; 49:708-712 (Pubitemid 351717534)
12. 18F]FDG-PET in the diagnosis of large-vessel vasculitis and the assessment of activity and extent of disease. Eur J Nucl Med Mol Imaging 2005; 32:674-681
13. Louis E, Ancion G, Colard A, Spote V, Belaiche J, Hustinx R. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/ CT. J Nucl Med 2007; 48:1053-1059
14. Inoue K, Goto R, Okada K, Kinomura S, Fukuda H. A bone marrow F-18 FDG uptake exceeding the liver uptake may indicate bone marrow hyperactivity. Ann Nucl Med 2009; 23:643-649
15. Ricci C, Longo R, Gioulis E, et al. Noninvasive in vivo quantitative assessment of fat content. J Hepatol 1997; 27:108-113
16. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]- fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850
17. Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. RadioGraphics 2006; 26:1637-1653
18. Dupont WD, Plummer WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19:589-601
19. 18F FDG-PET/CT. J Nucl Med 2008; 49[suppl 1]:263P
20. Sugawara Y, Zasadny KR, Neuhoff AW, et al. Re-evaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999; 213:521-525
21. Minn H, Zasadny KR, Quint LE, Wahl RL. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology 1995; 196:167-173
22. Weber WA, Ziegler SI, Thödtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999; 40:1771-1777
23. Dizendorf E, Hany TF, Buck A, von Schulthess GK, Burger C. Cause and magnitude of the error induced by oral CT contrast agent in CT-based attenuation correction of PET emission studies. J Nucl Med 2003; 44:732-738
24. 18F-FDG PET in malignant tumors. J Nucl Med 2008; 49:1804-1808
25. Bural G, Torigian D, Houseni M, Alkhawaldeh K, Alavi A. Comparison of the metabolic burden of the liver in patients with diffuse hepatic steatosis and normal control subjects. J Nucl Med 2006; 47[suppl 1]:149P
26. Abele JT, Fung CI. Effect of hepatic steatosis on liver FDG uptake measured in mean standard uptake values. Radiology 2010; 254:917-924